Ceftobiprole medocaril for skin and skin-structure infections DOI
Matthew W. McCarthy

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: March 3, 2025

Introduction On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection treatment of adults with acute bacterial skin structure infections (ABSSSI) as well patients Staphylococcus aureus bloodstream three months to less than 18 years old community-acquired pneumonia.

Language: Английский

Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: Expert opinion based on literature and real-life experiences DOI

Ivan Gentile,

Simone Giuliano, Silvia Corcione

et al.

Expert Review of Anti-infective Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Community-acquired pneumonia (CAP) and hospital-acquired (HAP) are major global health challenges, with high morbidity mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness standard empirical antibiotics, highlighting need for broader-spectrum agents that target also MDR organisms. This review summarizes findings from a PubMed search on use ceftobiprole in CAP HAP. It highlights key features ceftobiprole, including its mechanism action broad spectrum activity against multiple pathogens. Clinical data randomized controlled trials real-world studies underscore non-inferiority to treatments, favorable safety profile clinical cure rates even challenging cases. Ceftobiprole represents valid option patients Its main advantages include activity, making it valuable therapeutic choice treating polymicrobial infections, profile, which makes good candidate elderly comorbidities polypharmacy. Caution is advised at risk ESBL-producing organisms or Pseudomonas aeruginosa where combination therapy recommended. Moreover, drug monitoring recommended improve outcomes, particularly complex conditions.

Language: Английский

Citations

1
In Vitro Activity of Ceftobiprole against 20,255 Recent Clinical Bacterial Isolates in Canada (CANWARD 2015-2023) DOI

Élodie Gemme,

Andrew Walkty,

Melanie Baxter

et al.

Diagnostic Microbiology and Infectious Disease, Journal Year: 2025, Volume and Issue: 112(4), P. 116838 - 116838

Published: April 11, 2025

Language: Английский

Citations

0
Ceftobiprole medocaril for skin and skin-structure infections DOI
Matthew W. McCarthy

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: March 3, 2025

Introduction On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection treatment of adults with acute bacterial skin structure infections (ABSSSI) as well patients Staphylococcus aureus bloodstream three months to less than 18 years old community-acquired pneumonia.

Language: Английский

Citations

0